PIN1 and cancer: In this approach, Sulfopin, or a combination of ATRA and ATO were used to inhibit Pin1, and it highlights the potential of potent Pin1-inhibitors for clinical treatment either on their own or in combination with immunochemotherapy to render aggressive and resistant cancers curable (Koikawa et al., 2021).